Trigen Limited

TGN

cardiovascular pharmaceuticals; antithrombotics; anticoagulants; antidotes; preparations for inhibiting proteases for surgical or medical use;

TRIGEN

TECHNICAL CONSULTATION, INFORMATION AND ADVISORY SERVICES IN THE FIELD OF CHEMISTRY, BIOTECHNOLOGY, PHARMACOLOGY, MEDICINE AND PHARMACEUTICALS; AND LICENSING AND SALE OF INTELLECTUAL PROPERTY;Color is not a part of the mark. The stippling in the drawing is not intended to indicate color.;

TRIGEN

pharmaceutical and veterinary preparations and substrances, namely pharmaceutical preparations and substances for use in treating cardiovascular diseases; pharmaceutical preparations and substances for use in inhibiting blood clotting; pharmaceutical preparations and substances for use in treating or preventing thrombosis; diagnostic reagents for clinical or medical use;Color is not a part of the mark. The stippling in the drawing is not intended to indicated to indicate color.;

TRIGEN

Printed matter, namely, publications in the nature of booklets, reports, brochures, and prospectuses, all of the aforesaid relating to pharmaceutical research projects, molecular biology, chemistry, disease and/or intellectual property, but not including goods relating to anti-cancer vaccines; publications and documents, in the nature of booklets, reports, brochures, prospectuses, statements, presentations, fact sheets, and information releases, of a pharmaceutical research and/or development company, but not including goods relating to anti-cancer vaccines;

TRIGEN

Pharmaceutical research and pharmaceutical development services, namely, research and development services to find and develop new pharmaceutical products for others to put on the market; the provision of reports and information relating to chemicals, biological products, the preparation of either, formulations, candidate pharmaceutical products, pharmaceutical research projects, pharmaceutical research services, chemistry, molecular biology, and disease; conducting investigations and research in the field of pharmaceuticals to obtain information and data, to be supplied to others, relating to drugs, formulations and candidate pharmaceutical products; providing reports and information relating to intellectual property rights; and none of the foregoing services relating to anticancer vaccines;

TRIGEN

Intravenous anticoagulant for prevention of coagulation during coronary bypass graft; intravenous anticoagulant for prevention of coagulation during percutaneous coronary intervention; intravenous anticoagulant for prevention of coagulation during vascular surgery;

TRIGEN ADVANCING CARDIOVASCULAR CARE

The mark consists of the word TRIGEN next to a stylized oval, all above the words ADVANCING CARDIOVASCULAR CARE.;pharmaceutical preparations and substances; pharmaceutical preparations and substances for use in treating cardiovascular diseases or for use in treating disorders involving cellular proliferation; pharmaceutical preparations and substances for use in relation to occlusive or inflammatory cardiovascular disorders; cardioprotectants; pharmaceutical preparations and substances for use in inhibiting blood clotting; pharmaceutical preparations and substances for use in treating or preventing thrombotic disorders; diagnostic products for medical purposes; coagulation enzyme inhibitors; anti-thrombotic products; thrombolytic products; products for use in controlling angiogenesis; coating materials and impregnating materials for surgical, medical and dental apparatus and instruments, for example implants and prostheses; physiologically active products for surgical, medical or dental use; products having biological activity, for example anti-thrombogenic activity, for use in medicine, surgery or dentistry; products having biological activity, for example anti-thrombogenic activity, for use in coating or impregnating, or for use in the preparation of coatings or impregnants for, articles or equipment for medical or surgical use;The color(s) red (Pantone 187), yellow (Pantone 116) and a linear gradient blend thereof is/are claimed as a feature of the mark.;